SESSION TITLE: PAH
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Sunday, October 23, 2016 at 01:30 PM - 03:00 PM
PURPOSE: Pulmonary arterial hypertension (PAH) is a rare disease characterized by elevated pulmonary vascular resistance. Macitentan is an endothelin receptor antagonist indicated for the long-term treatment of PAH. This study presents consensus recommendations for managing macitentan and associated adverse events in PAH patients.